Veracyte, Inc. (VCYT)

Market Cap	2.91B -7.1%
Revenue (ttm)	517.15M +16.0%
Net Income	66.35M +174.9%
EPS	0.82 +164.5%
Shares Out	79.46M
PE Ratio	44.62
Forward PE	22.10
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,049,576
Open	37.93
Previous Close	38.75
Day's Range	36.40 - 38.60
52-Week Range	22.61 - 50.71
Beta	1.91
Analysts	Strong Buy
Price Target	46.50 (+27.08%)
Earnings Date	Feb 25, 2026

About VCYT

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It is also developing the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Oct 30, 2013
• Employees: 824
• Stock Exchange: NASDAQ
• Ticker Symbol: VCYT
• Website: https://www.veracyte.com

Financial Performance

In 2025, Veracyte's revenue was $517.15 million, an increase of 16.01% compared to the previous year's $445.76 million. Earnings were $66.35 million, an increase of 174.89%.

Analyst Summary

According to 8 analysts, the average rating for VCYT stock is "Strong Buy." The 12-month stock price target is $46.5, which is an increase of 27.08% from the latest price.

Price Target

$46.5

(27.08% upside)

Analyst Consensus: Strong Buy